Stevin Zorn is President and CEO at MindImmune Therapeutics, Inc., Kingston, RI, USA

• 1. Paul Greengard: A persistent desire to comprehend the brain, and also to fix itMarc Flajolet, Thu Lan N-Guyen, Vijay Kumar Siripuram and Yashoda Krishna Sunkari2. Giving names to the actors of synaptic transmission: The long journey from synaptic vesicles to neural plasticityFabio Benfenati, Martin Bähler and Flavia Valtorta3. cAMP-regulated phosphoproteins DARPP-32, ARPP16/19, and RCS modulate striatal signal transduction through protein kinases and phosphatasesKyle R. Christensen and Angus C. Nairn4. DARPP-32 40 years laterJean-Antoine Girault and Angus C. Nairn5. Effects of nicotine on DARPP-32 and CaMKII signaling relevant to addictionAngela M. Lee and Marina R. Picciotto6. Modulation of dendritic spines by protein phosphatase-1Jimcy Platholi and Hugh C. Hemmings Jr7. Deciphering cell-type specific signal transduction in the brain: Challenges and promisesJean-Pierre Roussarie and Patricia Rodriguez-Rodriguez8. Drug-activated cells: From immediate early genes to neuronal ensembles in addictionMarine Salery, Arthur Godino and Eric J. Nestler9. NAPE-specific phospholipase D regulates LRRK2 association with neuronal membranesFrancesca Palese, Silvia Pontis, Natalia Realini and Daniele Piomelli10. Amyloidogenic and anti-amyloidogenic properties of presenilin 1Victor Bustos, Maria Pulina and Jose Ledo11. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophreniaGretchen L Snyder, Kimberly E Vanover, Robert E Davis, Peng Li, Allen Fienberg and Sharon Mates12. Uniting homeostatic plasticity and exosome biology: A revision of the conceptual framework for drug discovery in neurodegenerative diseases?James K.T. Wang